Third-quarter sales of Forteo were $240.3 million, a 20 percent increase compared with the third quarter of 2010. U.S. sales of Forteo decreased 7 percent to $110.4 million due to decreased demand. Sales outside the U.S. increased 60 percent, to $129.9 million, due primarily to increased demand resulting from the recent launch in Japan, and, to a lesser extent, the favorable impact of foreign exchange rates.
During the third quarter of 2011, Strattera generated $153.2 million of sales, an increase of 20 percent compared with the third quarter of 2010. U.S. sales increased 13 percent to $96.3 million, due to higher prices and increased volume. Sales outside the U.S. increased 33 percent, to $56.8 million, driven primarily by higher demand in international markets including Japan and, to a lesser extent the favorable impact of foreign exchange rates.
Gemzar sales totaled $91.0 million in the third quarter of 2011, a decrease of 72 percent from the third quarter of 2010 due to generic competition in most major markets.
Lilly recognizes net royalties received from its Erbitux collaboration partners and revenue from manufactured product sold to these partners. For the third quarter of 2011, Lilly recognized total revenue of $97.2 million for Erbitux, an increase of 2 percent from the third quarter of 2010.
Exenatide (Byetta® and Bydureon)
Lilly recognizes in revenue its 50 percent share of Byetta's gross margin in the U.S., 100 percent of Byetta and Bydureon sales outside the U.S., and its sales of Byetta pen delivery devices to its partner, Amylin Pharmaceuticals. For the third quarter of 2011, Lilly recognized total exenatide revenue of $106.7 million, an increase of 4 percent.
Worldwide exenatide sales were $171.0 million in the third quarter of 2011, a 1 percent increase compared with the third qua
|SOURCE Eli Lilly and Company|
Copyright©2010 PR Newswire.
All rights reserved